Board Performance Report Performance Report€¦ · Board Performance Report Performance Report For the period ended 31st December 2017 Status Trend Comments Blood Components Stocks

Page 1 of 35

Board Performance Report Performance Report

For the period ended 31 st December 2017

S

tatu

s

T

rend

Comments

Blood Components

Stocks fell sharply to c25k during the month and have remained at that level to date. The underlying root cause has been under collection as a result of insufficient donor numbers of the right type/location. Stocks are expected to build post January month end but we remain vulnerable to the impact of flu / poor weather until they do.

DTS A positive income trend continues to be seen with overall year to date income growth of 10% for DTS overall. There have

now been 173 adult donor stem cell provisions versus 157 planned year to date (with international issues compensating for lower domestic use). Cornea stocks increased to 313 units by the end of December.

ODT

There were 129 deceased donors in December. Year to date deceased donors are 1.2% behind plan but are 7.5% higher than last year. The number of deceased transplants is now 6.5% lower than plan year to date but 4.4% higher than last year. Living Donors (reported one month in arrears) are 26% lower than plan in the year to date.

Corporate The focus on regulatory overdues has seen numbers decline over the last 2 months. Sickness absence was marginally

higher this month at 3.6%.

Finance

NHSBT is reporting a year to date deficit of £2.4m, £4.7m better than plan. The latest forecast is a £11.7m deficit versus £15.3m planned. The impact of reduced red cell demand and the costs of CSM are impacting the 5 year cash projection to a major degree with a significant cash gap in 2019/20 requiring cost reductions and/or price increases of around 10% to compensate.

Change Programme

The overall transformation programme continues to report at red status. The CSM project continues to report at red status, along with the Networks and Telephony project. Spend in total to date on CSM is £18.2m with £5m spend expected in Q4.

Contents Pages 1. Performance Summary 1 2. Financial Report 2-4 3. Blood Components - Summary 5-16 4. DTS – Summary 17-23 5. ODT – Summary 24-31 6. Group Level Trends 32-33 7. Risk Management 34-35

IncomePlan WTE

(Ave YTD)

Actual

WTE at

period

end

Budget Actual Variance2016-17

Actual

Full Year

BudgetForecast

£k £k £k £k £k £k

Revenue Cash Limit - Organ Donation & Transplantation 46,445 46,445 0 61,697 61,927 61,927

Revenue Cash Limit - Diagnostic and Therapeutic Services 3,130 3,130 0 4,173 4,173 4,173

Blood & Components Income 195,081 193,297 (1,785) 262,506 257,730 256,502

Diagnostic and Therapeutic Services Income 50,697 52,965 2,268 65,377 68,507 70,373

Research & Development 825 1,106 280 1,985 1,101 857

Organ Donation & Transplantation Other Income 9,046 8,982 (65) 11,544 12,062 11,984

All Other Income 5,246 5,366 120 7,266 7,001 6,919

Total Income 310,472 311,290 819 414,548 412,500 412,735

Expenditure

Cost of Sales - Blood Component Stock Movement (259) (962) (702) (143) 0 0

Cost of Sales - Tissues Stock Movement 0 (126) (126) 42 0 0

Organ Donation & Transplantation: Operational Expenditure 404 389 (44,663) (43,913) 749 (60,062) (59,601) (59,168)

Organ Donation & Transplantation: Change Programme 4 16 (3,593) (3,462) 132 (5,216) (6,526) (5,819)

Blood Supply: Manufacturing, Testing & Issue 794 741 (51,115) (51,313) (198) (69,589) (67,484) (67,799)

Blood Supply: Blood Donation 1,410 1,427 (54,609) (53,729) 880 (76,577) (72,309) (71,751)

Blood Supply: Logistics 350 334 (15,592) (15,741) (148) (21,175) (20,649) (21,052)

Diagnostic and Therapeutic Services 849 791 (45,864) (46,110) (246) (60,293) (61,113) (62,035)

Quality 83 87 (3,777) (3,752) 24 (4,783) (5,023) (5,042)

Chief Executive and Board 3 4 (466) (504) (39) (623) (621) (660)

Communications 73 72 (5,210) (5,137) 73 (7,397) (7,363) (7,363)

Estates & Facilities 77 76 (28,506) (28,382) 123 (40,182) (39,211) (39,363)

Finance 98 93 (4,193) (4,252) (59) (5,760) (5,573) (5,675)

Business Transformation Services 27 23 (1,247) (1,034) 213 (1,588) (1,662) (1,366)

Workforce 135 121 (5,783) (5,184) 599 (7,529) (7,710) (7,227)

Information Communication Technology 169 166 (17,112) (17,622) (511) (20,661) (22,814) (23,314)

Clinical Directorate 181 170 (10,766) (10,459) 307 (14,014) (14,168) (13,761)

Research & Development 33 39 (2,799) (3,083) (284) (5,627) (4,443) (4,443)

Change Programme (Blood & Corporate) 6 29 (20,760) (17,391) 3,369 (17,850) (27,842) (26,345)

Miscellaneous and Capital Charges (1,182) (1,486) (304) (439) (2,150) (2,215)

Total Expenditure 4,696 4,576 (317,495) (313,643) 3,852 (419,467) (426,263) (424,398)

Surplus/(Deficit) (7,023) (2,353) 4,671 (4,919) (13,762) (11,663)

Statutory Accounts Presentation

NHSBT Surplus/(Deficit) as above (7,023) (2,353) 4,671 (4,919) (13,762) (11,663)

Add back Notional Cost of Capital 5,238 5,238 0 7,323 7,121 7,121

Remove Revenue Cash Limit (49,575) (49,575) 0 (65,870) (66,100) (66,100)

Deduct Capital Charges Cash Payment (13,158) (13,158) 0 (17,292) (17,544) (17,544)

Net Expenditure (64,519) (59,848) 4,671 (80,758) (90,285) (88,186)

A deficit of £3.6m was reported in December,

£1.8m worse than plan.

Year to date NHSBT is reporting a deficit of £2.4m

versus a planned deficit of £7.0m. This is driven by

a favourable DTS contribution (£1.9m higher

income in TAS, SCDT and RCI), an in-year VAT

return (£1.8m), lower change programme costs in

both Blood/Group (£3.4m) and ODT (£0.9m),

partially offset by an adverse costs of sales

position (£0.7m - red cell stocks lower than

planned).

The current forecast for the year is a £11.7m

deficit (versus £13.8m budgeted). This is £3.2m

lower than the forecast last month, mainly

reflecting lower change programme spend (£2.3m)

and increased Blood Component income (£1.0m).

Balance sheet - current assets were £58.8m at the

end of December 2017 with a cash balance of

£49.9m (including capital charges payable of

£4.4m). The projected year end cash balance is

now £30m.

Debtor days were at 26 in December, equal with

last month, but higher than target of 22 days.

Year to date

NHSBT REVENUE STATEMENT - FOR THE PERIOD ENDED 31 DECEMBER 2017

Page 2 of 35

NHSBT CASH FLOW - FORECAST 2017/18

Actual Actual Actual Actual Actual Actual Actual Actual Act ual Forecast Forecast ForecastApr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec -17 Jan-18 Feb-18 Mar-18 Total

£k £k £k £k £k £k £k £k £k £k £k £k £k

Opening bank balance 32,755 30,381 51,874 37,988 50,333 54,137 51,918 48,521 50,507 49,920 47,209 37,305 32,755

ReceiptsDebtors & Other Receipts 19,729 34,209 25,544 35,518 32,118 28,783 34,402 29,645 30,683 27,730 28,784 37,980 365,125Revenue Cash Limit 0 16,525 0 5,508 5,508 5,509 5,508 5,508 5,509 5,508 5,508 5,509 66,100Capital Cash Limit 0 0 0 2,500 0 0 2,000 0 0 0 500 1,500 6,500 Total income 19,729 50,734 25,544 43,526 37,626 34,292 41,910 35,153 36,192 33,238 34,792 44,989 437,725

PaymentsStaff Expenses 9,778 16,766 16,853 16,745 16,520 17,999 17,230 17,055 16,628 16,671 16,689 22,933 201,867Other Revenue Payments 12,241 11,980 22,306 14,270 17,040 18,425 19,105 15,967 19,729 18,778 18,735 26,011 214,587Capital Charges 0 0 0 0 0 0 8,772 0 0 0 8,772 0 17,544Capital Payments 84 495 271 166 262 87 200 145 422 500 500 3,368 6,500 Total costs 22,103 29,241 39,430 31,181 33,822 36,511 45,307 33,167 36,779 35,949 44,696 52,312 440,498

Closing bank balance 30,381 51,874 37,988 50,333 54,137 51,918 48,521 50,507 49,920 47,209 37,305 29,982 29,982

Debtor Days (Target is 22 days) 28 20 24 20 19 27 23 26 26YTD BPPC By Value % (Target is 95%) 99.0% 97.3% 98.3% 98.6% 98.5% 98.6% 98.6% 98.7% 98.7%YTD BPPC By Number % (Target is 95%) 97.8% 97.9% 98.3% 98.2% 98.1% 97.9% 98.0% 97.8% 97.8%

Top 5 Overdue Debtors NBS/ODT £000'sTotal

Overdue £000's

1-30 Days overdue £000's

31-60 Days

overdue £000's

61-90 Days

overdue £000's

>90 Days overdue £000's

Comments

King's College Hospital NHS Foundation Trust 1,966 662 587 203 514 £466k received 08/01 - remainder invoices not authorised Cambridge University Hospitals NHS Foundation Trust 774 425 321 8 20 Invoices not authorised for paymentImperial College Healthcare NHS Trust 760 349 103 74 234 £200k received 08/01 - remainder invoices not authorised Barking, Havering & Redbridge Hospitals NHS Trust 715 160 152 173 230 £617k received 02/01 - remainder invoices not authorised Buckinghamshire Healthcare NHS Trust 696 149 159 144 244 Invoices not authorised for payment

Page 3 of 35

Year to date Actual £mBlood &

Components inc. R&D

RCI H&I Reagents IBGRL Tissues CMT CBC BBMR CBB TAS ODT TOTAL

IncomePrices 196.1 10.2 10.0 1.2 0.9 9.6 7.0 - 2.8 0.9 6.8 - 245.6Central Funding from DHAs - - - - - - - - - - - 8.9 8.9Grant in Aid - - - - - - - 0.0 1.3 1.7 - 46.4 49.4Other 3.8 0.3 0.3 - - - 0.6 1.0 0.1 0.9 0.4 0.1 7.4

Total Income 199.9 10.5 10.3 1.2 0.9 9.6 7.6 1.0 4.2 3.4 7.2 55.4 311.3

ExpenditureVariable Costs

Consumables (30.8) (0.8) (2.7) (0.4) (0.2) (1.4) (1.4) (0.3) (0.5) (0.4) (2.6) (2.6) (43.8)Other - - - - - - - - - - - - -

Total Variable Costs (30.8) (0.8) (2.7) (0.4) (0.2) (1.4) (1.4) (0.3) (0.5) (0.4) (2.6) (2.6) (43.8)

Variable Contribution 169.1 9.7 7.6 0.9 0.7 8.2 6.2 0.7 3.7 3.1 4.6 52.9 267.5

Direct CostsPay (65.0) (5.5) (4.8) (0.6) (0.9) (4.9) (3.0) (0.6) (1.0) (1.6) (1.9) (18.8) (108.6)Non Pay (15.5) (0.5) (0.7) (0.1) (0.1) (2.2) (0.6) (0.2) (0.7) (0.4) (0.6) (22.9) (44.5)

Total Direct Costs (80.5) (6.0) (5.5) (0.6) (1.0) (7.1) (3.6) (0.8) (1.7) (2.0) (2.5) (41.8) (153.1)

Direct Contribution 88.6 3.8 2.1 0.2 (0.3) 1.1 2.6 (0.1) 2.0 1.1 2.2 11.1 114.4

Direct SupportOperational Directorate costs (4.1) (0.1) (0.1) (0.0) (0.0) (0.1) (0.1) (0.0) (0.0) (0.0) (0.1) (0.9) (5.7)Logistics (15.4) (0.1) (0.0) (0.0) - (0.0) (0.0) - (0.0) (0.1) (0.1) (0.0) (15.7)Clinical (6.6) (0.3) - - - (0.1) (0.1) - (0.1) (0.1) (0.2) (0.7) (8.3)Attributable Estates costs (15.9) (0.9) (0.7) (0.1) (0.3) (1.0) (1.0) (0.0) (0.1) (0.1) (0.1) (0.9) (21.2)Attributable IT costs (3.2) (0.1) (0.1) (0.0) (0.0) (0.0) (0.0) - (0.0) (0.0) (0.0) (1.8) (5.4)

Depreciation / Cost of CapitalDepreciation / Cost of Capital (1.5) (0.2) (0.3) (0.0) (0.1) (0.2) (0.4) (0.1) (0.1) (0.1) (0.2) (0.4) (3.6)Total Direct Support (46.7) (1.8) (1.2) (0.2) (0.5) (1.5) (1.6) (0.1) (0.5) (0.5) (0.6) (4.8) (59.9)

Notional Internal Income Uplift (1.6) (0.1) 1.5 0.2 0.3 0.0 0.0 (0.0) (0.4) 0.0 0.0 (0.0) (0.0)Cost of Sales (1.0) - - - - (0.1) - - - - - - (1.1)

Contribution to Unallocated Costs 39.4 1.9 2.4 0.2 (0.5) (0.5) 1.1 (0.3) 1.1 0.6 1.6 6.3 53.4

Total Allocated Costs (160.5) (8.6) (7.9) (1.0) (1.4) (10.1) (6.5) (1.3) (3.1) (2.9) (5.6) (49.2) (257.9)

Unallocated Costs ApportionedDirectorate costs (15.6) (0.8) (0.7) (0.1) (0.1) (0.9) (0.6) (0.1) (0.3) (0.3) (0.5) (4.6) (24.5)Estates costs (4.6) (0.2) (0.2) (0.0) (0.0) (0.3) (0.2) (0.0) (0.1) (0.1) (0.1) (1.4) (7.2)Depreciation / Cost of Capital (2.1) (0.1) (0.1) (0.0) (0.0) (0.1) (0.1) (0.0) (0.0) (0.0) (0.1) (0.6) (3.2)

Total Unallocated Costs (22.3) (1.1) (1.0) (0.1) (0.2) (1.3) (0.8) (0.2) (0.4) (0.4) (0.7) (6.6) (34.9)

Operating Net Surplus / (Deficit) 17.1 0.9 1.4 0.1 (0.7) (1.7) 0.3 (0.4) 0.8 0.2 0.9 (0.3) 18.5

Transformation Costs (17.4) - - - - - - - - - - (3.5) (20.9)

Total Allocated Costs Inc Transformation (177.9) (8.6) (7.9) (1.0) (1.4) (10.1) (6.5) (1.3) (3.1) (2.9) (5.6) (52.6) (278.7)

Net Surplus / (Deficit) Inc Transformation (0.3) 0.9 1.4 0.1 (0.7) (1.7) 0.3 (0.4) 0.8 0.2 0.9 (3.8) (2.3)

RAG STATUS (Actuals V Plan) G G G G G R G G G G G G G

R&D PROGRAMME COSTS (3.0) (0.7) (0.1) - - (0.3) (0.4) - - - - (0.0) (4.6)

NHSBT HIGH LEVEL ABC CONTRIBUTION ANALYSIS FOR THE PERIOD ENDED 31 DECEMBER 2017

Diagnostics Stem Cells

Page 4 of 35

Page 5 of 35

DIVISION PILLAR BLOOD 2020 – STRATEGIC TARGETS YTD RAG

RAG CHANGE

PERFORMANCE

72% of blood donors scoring =/> 9/10 for satisfaction. G - 78.7% vs plan of 75% – Chart 21.

No. of complaints per million donation G - 0.38% vs plan of 0.44% – Chart 22

% of whole blood donations in donor centres G - Month at 20.0%.

% of 9 bed sessions G - 71.0% vs plan of 80%.

Blood Donation Productivity: units/FTE/year G - 1,395 vs plan of 1,410 – charts 29/30.

Number of Donors Donating over the last 12 months (000’s) R Worse 825.0k vs plan of 842.9 – Chart 23.

Frequency of Donation (overall) G -- 1.86 (vs 1.85 planned) - (Chart 23).

Number of O- neg Donors donating last 12 months (000’s) R - 103.4k vs 107.1k planned – Chart 24.

Frequency of Donation (O neg donors) A - 1.96 versus 1.91 planned – Chart 24.

Blood Donation and the Donor Experience

Recruitment of new Ro donors - 7k R - 2.8k versus 5.8k target

Red Cell Blood Stocks – Alert Levels R Worse Above 3 day alert on 2 occasions– chart 14/15.

Platelet Demand vs. Stock levels R - Stocks were below target - 2 occasions in month.

Number of ‘critical’ and “major” regulatory non-compliances G - None reported in the month.

97% of Products Issued on Time A - On target at 96.9% – chart 3.

Manufacturing Productivity (units/FTE/year) A - 10.1k vs 10.3k planned – Chart 27.

BLOOD

Supply-Chain Operations

Testing Productivity (units/FTE/year) A - 28.9k vs plan of 29.7k – Chart 28.

Page 6 of 35

DIVISION PILLAR BLOOD 2020 – STRATEGIC TARGETS YTD RAG

RAG CHANGE

PERFORMANCE

BLOOD Supply Chain Operations

70 % hospitals scoring =/> 9/10 for satisfaction (chart 4). A - December at 66% (better than target). Next survey March 2018

• Issues in December were 1.9% higher than forecast (with a large demand seen in w/c 18 December). In addition, Collections were 2% lower than plan

(especially during w/c 11 December as a result of snow/ice) and hence stocks fell sharply to c25k around mid month (c 4.5 days) and have stayed at this level to date. Stocks being at this level (and with low levels of O negative and B negative), for his period of time, is unprecedented and we remain vulnerable to poor weather (and short term demand fluctuation) until they can be built back to above 6 days.

• Although stocks were specifically impacted in the month by short term issues we entered December with lower stocks than planned (and with the vulnerable

groups already low) and hence did not have the headroom to cope with the fluctuation seen. In turn, this reflects under collection over the past few months as a result of falling numbers of active donors of the right group / locations and an inability to effectively utilise our deployed capacity. The total number of active whole blood donors, and the number of active O neg (and B neg) donors are both below plan, with the latter at red status and continuing to fall (charts 23 and 24).

• During December, efforts were focused on improving stock availability via pushing work in progress and, during January, collections have been well above

plan (especially the first week of January). Demand, however, continues to be comparatively high and we anticipate that stocks will remain at ca 25k through January before stocks start to build.

• Due to the donor shortfall, collection capacity is having to being retained, rather than being reduced in line with falling demand over the longer term. As a

result productivity is starting to fall (chart 27), as well as capacity utilisation, and will run significantly short of Blood 2020 targets. Marketing costs will also require a significant increase to re-build the donor base (an additional £2m is being assumed for 2018/19).

• The proportion of O neg issues to total issues was higher this month at 13.6% and, in the year to date, is at 13.4% (versus 13.1% for full year 2016/17).

Demand however, appears to be falling and may reflect NBTC guidance to use O positive in massive trauma cases where possible. • OTIF in December was 96.6% (versus 97% target) with the year to date marginally below target at 96.9%. The two main drivers of the OTIF fails continue to

be insufficient supply of Ro red cells to met hospital requests (36% of total) and ‘Timing Only’ fails (39% of the total). By centre, Tooting, Colindale and Basildon continue to record the highest numbers of Ro fails. Timing only performance decreased in December mainly due to Manchester and ongoing ordering protocol issues with the Central Manchester Foundation Trust.

• In order to meet the increasing Ro demand £1m has been set aside from transformation funds to pay for the recruitment of black donors and we would expect

to fully spend this by year end. At the end of December the number of active black blood donors continues to be much lower than planned (11,160 vs 18,846), compounded by a lower than anticipated conversion rate for new recruits. As a result the increase in new black donors donating is much lower than planned (3,612 in the year to date vs 10,478 planned).

Page 7 of 35

• The red cell loss rate was higher in December at 4.91% with the year to date (4.57%) higher than both plan (3.60%) and previous year (3.86%). Red cell process losses are now well in excess of historic levels and continue to develop adversely.

• The red cell expiry rate was lower in December at 1.20% with the year to date (1.51%) also higher than the previous year (1.29%) and target (1.25%). At a

group level 983 of the 1,398 red cell expiries in the month were A negative and continues to reflect over collection of A negative whole blood to manufacture platelets (in lieu of a lack of A negative CD platelet donors).

• Platelet stocks in December came under significant pressure during the month with 15 out of 19 working days between 1-2 days stock and below the 1 day

alert on the 6th December and two alert level notifications to hospitals during the month. At a group level group A- and AB- was below the alert level on 3 days. Early January has seen a continuation of the trend with overall stocks lower than the alert level on the 4th January 2018 and with the majority of working days between 1-2 days stock. Additionally groups A+ and AB- have been below the alert level on two consecutive days.

• Platelet donors (in total and for A negative) continue to be around 10% lower than plan albeit the numbers appear to have stabilised with the attrition over the

last few months halted. Until donor numbers are increased the expiry of A negative red cells (above) will continue to be high.

• The number of faints in the month was better at 158 and better than target (160). The number of rebleeds was higher than last month at 30 although level with target (30).

• Donor satisfaction improved this month to 79% and continues to be better than plan (75%). Donor complaints (excluding those complaints related to consolidation /

team closures and also those related to cancellation of sessions) were better this month at 3.8k (November 3.9k), and also better than plan of 4.4k. The primary drivers for complaints are “cancellation of session”, “slot availability”, “not seen at appointment time” and also “staff attitude”. Work is ongoing to review our SMS communications with donors and with a stakeholder workshop planned.

• Sickness absence in logistics was marginally worse this month at 4.7%

• There was 1 SABRE reportable events this month - this related to an irradiated unit labeling error.

• There were no major/critical non-compliances reported this month. • The demand forecast for red cells in 2017/18 has improved slightly this month to 1.439m (1.434m last month) although it continues to be lower than the level

agreed with NCG of 1.461m units. The demand forecast for 2018/19 of 1.398m units, agreed with the NCG in early November, has been revised downward to 1.390m. Platelet demand has remained unchanged at 0.260m for 17/18 through to 19/20.

Year 2016-17 actual

2017-18 forecast

2018-19 forecast

2019-20 forecast

2020-21 forecast

2021-22 forecast

Red cell issues (million) 1.522 1.439 1.390 1.333 1.282 1.231

% change vs 2016/17 - -5.5% -8.7% -12.4% -15.8% -19.1%

Page 8 of 35

• The 5 year financial projection is materially impacted by the costs of CSM and the impact of lower demand. In addition, the removal of the 1% pay inflation cap in 2018/19 and now also higher marketing costs (to correct both the current donor shortfall but also the risk from the impact of the Interval/Compare studies) are further impacting the projection, despite a successful round of costs savings over the last few months. On current projections there will be a significant cash shortfall from 2019/20 onwards and, although the 2018/19 price rise has reduced the impact, further significant price increases and/or cost reductions will be required to establish a robust financial position.

Blood Supply - Status of Strategic Projects per TPB reporting:

Project title Status This RAG

Last RAG

Approved Cost

(£m’s)

F/Cast Cost

(£m’s)

F/cast Benefit (£m’s)

Planned to

complete

F/Cast to

complete Supply Chain Modernisation (National Operations) Delivery G G 6.5 6.5 1.4 Oct 17 Jan 18

Core Systems Modernisation Delivery R R 11.4(i) (1.6) 14.8 1.2 Jan 20 Dec 19

Euro Blood Pack 2 Delivery A A 0.4 0.3 0.7 Aug 18 Jun 18 Leicester Mobile Team Base & Donor Centre Relocation Delivery A R 1.2 1.2 0.1 May 18 Oct 18

HEV Universal Screening Delivery A A N/A(ii) N/A N/A Jan 18 Jan 18 SotF – Session Connectivity Pilot Start-Up G G 0.1 0.1 0.3 May 18 Nov 18 SotF – Continuous Care Delivery G G 0.8 0.8 1.4 Apr 19 Apr 19 SotF – Unconstrained Supply Plan Delivery G G 1.7 N/A N/A Nov 18 Nov 18 E-Rostering Delivery G G 0.2 0.2 N/A Apr 18 Jul 18 NTMRL Database Upgrade Delivery A A 0.1 0.1 N/A Jan 18 Mar 18 West End Donor Centre Expansion Start-Up G N/A 0.5 0.5 0.4 N/A Jan 19

Notes: i) This is the non-recurring figure for 2017/18. Recurring figure in brackets. ii) No project budget required – contract related costs are not part of project budget.

1. Major QIs raised per month - Blood Supply Directorate 2. % of Patients Receiving Grade A or B1 HLA Matched Platelets H&I # 5

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

75.0% 75.0% 71.2% A -

3. Percentage of Products Issued OTIF BC # 1

Annual

Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG

Trend

Annual

Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG

Trend

97.00% 97.00% 96.89% A - 70% 70% 66% A Worse

YTD Performance

% On Time In Full delivery

4. Hospital Satisfaction

YTD Performance

Hospitals rating satisfaction at >/=9/10

Blood Components - Blood Collection: Customer Service

Monthly Performance Report - As at the end of December 2017

Blood Components - Safety and Compliance

YTD Performance

% of patients receiving A or B1

platelets

0

10

20

30

40

50

60Jan

-17

Feb

-17

Ma

r-1

7

Apr-

17

Ma

y-1

7

Jun

-17

Jul-1

7

Aug-1

7

Sep-1

7

Oct-

17

No

v-1

7

De

c-1

7

Blood Donation Manufacturing & Logistics

0.0%

10.0%

20.0%

30.0%

40.0%

50.0%

60.0%

70.0%

80.0%

Jan-1

7

Fe

b-1

7

Ma

r-1

7

Ap

r-1

7

Ma

y-1

7

Ju

n-1

7

Jul-17

Aug-1

7

Sep-1

7

Oct-

17

No

v-1

7

De

c-1

7

Grade A Grade B1 Target

90.0%

91.0%

92.0%

93.0%

94.0%

95.0%

96.0%

97.0%

98.0%

99.0%

100.0%

Jan-1

7

Feb

-17

Ma

r-1

7

Apr-

17

Ma

y-1

7

Jun-1

7

Jul-1

7

Aug-1

7

Sep-1

7

Oct-

17

No

v-1

7

De

c-1

7OTIF Actual OTIF Plan

70% 70% 70% 70%

76%

84%

76%

66%

50%

55%

60%

65%

70%

75%

80%

85%

90%

Ma

r-1

7

Jun-1

7

Sep-1

7

De

c-1

7

Plan Actual

Monthly Performance Report: As at the end of December 2017 Page 9 of 35

5. Average Weekday Red Cell Issues By Month ->April 2015 6. MAT Red Cells and O Neg Issues (Adult Equivalant Units) - 000's

7. Red Cell Supply - Year to Date by Blood Group

O Pos

A Pos

O Neg

A Neg

B Pos

B Neg

AB Pos

AB Neg


Blood Components - Red Cell Issues

Blood Group2017/18 - YTD

Dec 2017

2016/17 - YTD

Dec 2016Change

8. RO Red Cells Requested, Validated and Issued

385,919 407,442 -5.3%

27,089 28,213 -4.0%

85,267 89,998 -5.3%

86,464 93,873 -7.9%

321,327 340,870 -5.7%

Total 1,083,248 1,143,554 -5.3%

144,880 149,899 -3.3%

8,622 9,058 -4.8%

23,680 24,202 -2.2%

140

145

150

155

160

165

170

175

180

185

190

195

200

205

210

215

220

1,400

1,450

1,500

1,550

1,600

1,650

1,700

1,750

1,800

1,850

1,900

1,950

2,000

2,050

2,100

2,150

2,200

Ap

r-1

0

Ju

l-1

0

Oct-

10

Jan-1

1

Apr-

11

Jul-1

1

Oct-

11

Jan-1

2

Apr-

12

Jul-1

2

Oct-

12

Jan-1

3

Ap

r-1

3

Ju

l-1

3

Oct-

13

Ja

n-1

4

Ap

r-1

4

Jul-1

4

Oct-

14

Jan-1

5

Apr-

15

Jul-1

5

Oct-

15

Jan-1

6

Apr-

16

Jul-1

6

Oct-

16

Ja

n-1

7

Ap

r-1

7

Ju

l-1

7

Oct-

17

O N

eg

Is

su

es

Re

d C

ell

Is

su

es

(in

cl.

O n

eg

)

Red Cell Issues (all groups) MAT Red Cell Issues (O Neg) MAT

000's000's

4,500

4,700

4,900

5,100

5,300

5,500

5,700

5,900

6,100

6,300

Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar

Ave

rag

e W

ee

kd

ay I

ss

ue

s

2015/16 2016/17 Plan 1,434k Initial Plan 2017/18

Latest data point is part month

0

500

1,000

1,500

2,000

2,500

3,000

3,500

4,000

4,500

5,000

Apr-

15

May-1

5

Jun

-15

Jul-

15

Aug-1

5

Sep-1

5

Oct-

15

No

v-1

5

De

c-1

5

Jan

-16

Feb-1

6

Mar-

16

Ap

r-16

Ma

y-1

6

Jun

-16

Jul-

16

Aug-1

6

Sep-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan-1

7

Fe

b-1

7

Ma

r-1

7

Ap

r-17

Ma

y-1

7

Jun-1

7

Jul-

17

Aug-1

7

Sep-1

7

Oct-

17

Nov-1

7

De

c-1

7

Jan

-18

Fe

b-1

8

Ma

r-1

8

RO Requested RO Validated RO Issued


9. Average Weekday Platelet Issues By Month ->April 2014 10. MAT Platelet and A Neg Issues (Adult Therepeutic Doses) - 000's

11. MAT UK (Non MB) FFP and UK (Non MB) Cryo Pools - 000's 12. MAT Meth Blue FFP and Meth Blue Cryo Pools


Blood Components - Platelet Issues

Blood Components - Frozen Component Issues

0

500

1,000

1,500

2,000

2,500

3,000

3,500

3,000

4,000

5,000

6,000

7,000

8,000

9,000

10,000

Ma

r-10

Jun

-10

Se

p-1

0

Dec-1

0

Ma

r-11

Jun

-11

Se

p-1

1

Dec-1

1

Ma

r-12

Jun

-12

Se

p-1

2

Dec-1

2

Ma

r-13

Jun

-13

Se

p-1

3

Dec-1

3

Mar-

14

Jun

-14

Se

p-1

4

Dec-1

4

Ma

r-15

Jun

-15

Se

p-1

5

Dec-1

5

Ma

r-16

Jun

-16

Se

p-1

6

Dec-1

6

Ma

r-17

Jun

-17

Se

p-1

7

Dec-1

7

Meth

Blu

e F

FP

MAT : MB FFP MAT : MB Cryo Pools

18

20

22

24

26

28

30

32

34

36

150

160

170

180

190

200

210

220

230

240

250

260

270

Mar-

10

Jun

-10

Se

p-1

0

Dec-1

0

Mar-

11

Jun

-11

Se

p-1

1

Dec-1

1

Mar-

12

Jun

-12

Se

p-1

2

Dec-1

2

Mar-

13

Jun

-13

Se

p-1

3

Dec-1

3

Mar-

14

Jun

-14

Se

p-1

4

Dec-1

4

Mar-

15

Jun

-15

Se

p-1

5

Dec-1

5

Mar-

16

Jun

-16

Se

p-1

6

Dec-1

6

Mar-

17

Jun

-17

Se

p-1

7

Dec-1

7

UK

Cry

o P

oo

ls (

00

0s)

UK

FF

P (

000s

)

MAT : UK FFP (000s) MAT : UK Cryo Pools (000s)

26

30

34

38

42

200

220

240

260

280

300

320

Apr-

12

Jul-1

2

Oct-

12

Jan-1

3

Apr-

13

Jul-1

3

Oct-

13

Jan-1

4

Apr-

14

Jul-1

4

Oct-

14

Jan-1

5

Apr-

15

Jul-1

5

Oct-

15

Jan-1

6

Apr-

16

Jul-1

6

Oct-

16

Jan-1

7

Apr-

17

Jul-1

7

Oct-

17

A n

eg

Issu

es

AT

D P

late

let

Issu

es (

incl. A

neg

)

Platelet Issues (all groups) MAT Platelet Issues (A Neg) MAT

000's 000's

750

770

790

810

830

850

870

890

910


Ave

rag

e W

ee

kd

ay I

ss

ue

s

2015/16 2016/17 Plan 261k 2017/18

Latest data point is part month

Me

th B

lue

Cry

o P

oo

ls


13. Red Cell - Blood Stocks (Units)

15. Red Cell - O neg : weekday stock levels BC # 3 16. Platelet - Total and A neg : weekday stock levels BC # 4

YTD PerformanceAnnual

Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG

TrendYTD Performance

Annual

Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG

Trend

Number of occasions where red cell stocks (for

any blood group) are below the three day alert

level for three or more consecutive days

0 0 2 R Worse

Number of occasions where opening stock of

platelets (for any blood group) is below average

daily demand for two or more consecutive days

0 0 24 R -


Blood Components - Stocks

14. Average Red Cell Stock Levels for the month by blood group

1.50

2.50

3.50

4.50

5.50

6.50

7.50

16-J

an

-17

30-J

an

-17

13-F

eb

-17

27-F

eb

-17

13-M

ar-

17

27-M

ar-

17

10-A

pr-

17

24-A

pr-

17

08-M

ay-1

7

22-M

ay-1

7

05-J

un

-17

19-J

un

-17

03-J

ul-

17

17-J

ul-

17

31-J

ul-

17

14-A

ug-1

7

28-A

ug-1

7

11-S

ep-1

7

25-S

ep-1

7

09-O

ct-

17

23-O

ct-

17

06-N

ov-1

7

20-N

ov-1

7

04-D

ec-1

7

18-D

ec-1

7

01-J

an

-18

O- AlertDays stock

0.00

0.75

1.50

2.25

3.00

3.75

01-J

un-1

7

08-J

un-1

7

15-J

un-1

7

22-J

un-1

7

29-J

un-1

7

06-J

ul-17

13-J

ul-17

20-J

ul-17

27-J

ul-17

03-A

ug-1

7

10-A

ug-1

7

17-A

ug-1

7

24-A

ug-1

7

31-A

ug-1

7

07-S

ep-1

7

14-S

ep-1

7

21-S

ep-1

7

28-S

ep-1

7

05-O

ct-

17

12-O

ct-

17

19-O

ct-

17

26-O

ct-

17

02-N

ov-1

7

09-N

ov-1

7

16-N

ov-1

7

23-N

ov-1

7

30-N

ov-1

7

07-D

ec-1

7

14-D

ec-1

7

21-D

ec-1

7

28-D

ec-1

7

04-J

an-1

8

11-J

an-1

8

Total Platelet Stocks Alert Level A-

20,000

25,000

30,000

35,000

40,000

45,000

Ja

n

Fe

b

Ma

r

Ap

r

Ma

y

Jun

Ju

l

Au

g

Se

p

Oct

No

v

De

c

Yr to 13 Jan 2017 Yr to 12 Jan 2018

5.3

6.35.8

8.4

4.0

10.2

3.3

7.7

5.9

0

1

2

3

4

5

6

7

8

9

10

11

12

O+ A+ B+ AB+ O- A- B- AB- Total

Arrows indicate change from last month

Day

s St

ock


17. O neg RC Demand and Issues 18. A neg Platelet Demand and Issues

19. Percentage of Donations NOT Converted to Validated Red Cells and Expiries 20. Percentage of Platelets Produced NOT Issued


Blood Components - Red Cell Demand/Issues (O Neg) and Platelet Demand/Issues (A Neg)

Blood Components - Wastage

12000

13000

14000

15000

16000

17000

18000

19000

41730 41821 41913 42005 42095 42186 42278 42370 42461 42552 42644

O- Demand O- Issues

12,000

13,000

14,000

15,000

16,000

17,000

18,000

19,000

Apr-

14

Ju

n-1

4

Aug

-14

Oct-

14

Dec-1

4

Feb

-15

Apr-

15

Ju

n-1

5

Aug

-15

Oct-

15

Dec-1

5

Feb

-16

Apr-

16

Ju

n-1

6

Aug

-16

Oct-

16

Dec-1

6

Feb

-17

Apr-

17

Ju

n-1

7

Aug

-17

Oct-

17

Dec-1

7

O- Demand O- Issues

2,000

2,200

2,400

2,600

2,800

3,000

3,200

3,400

3,600

3,800

4,000

4,200

Ap

r-1

4

Ju

n-1

4

Au

g-1

4

Oct-

14

Dec-1

4

Feb

-15

Apr-

15

Ju

n-1

5

Aug-1

5

Oct-

15

Dec-1

5

Feb

-16

Ap

r-1

6

Ju

n-1

6

Au

g-1

6

Oct-

16

Dec-1

6

Feb

-17

Apr-

17

Ju

n-1

7

Aug-1

7

Oct-

17

Dec-1

7

A- Demand A- Issues

0.00%

0.50%

1.00%

1.50%

2.00%

2.50%

3.00%

3.50%

4.00%

4.50%

5.00%

5.50%

6.00%

20

10

/11 F

Y

20

11

/12 F

Y

20

12

/13 F

Y

20

13

/14 F

Y

20

14

/15 F

Y

20

15

/16 F

Y

20

16

/17 F

Y

Ap

r-17

May-1

7

Ju

n-1

7

Ju

l-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

Ja

n-1

8

Fe

b-1

8

Mar-

18

Actual Process Losses Plan Process Losses Actual Expiries Plan Expiries

0.00%

2.50%

5.00%

7.50%

10.00%

12.50%

15.00%

17.50%

20.00%

22.50%

20

10

/11 F

Y

20

11

/12 F

Y

20

12

/13 F

Y

20

13

/14 F

Y

20

14

/15 F

Y

20

15

/16 F

Y

20

16

/17 F

Y

Ap

r-17

May-1

7

Ju

n-1

7

Ju

l-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

Ja

n-1

8

Fe

b-1

8

Mar-

18

Period Total Pooled CD Plan


21. Donor Satisfaction BC # 5 22. Donor Complaints BC # 10


Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG


Annual

Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG

Trend

% of donors scoring >= 9/10 for satisfaction 75.0% 75.0% 78.7% G - Number of complaints per million donations 4,400 4,400 3,833 G -

23.Donor Base and Frequency of Donation BC # 6 BC # 7 24. O Neg: Donorbase and Frequency of Donation BC # 8 BC # 9


Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG


Annual

Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG

Trend

Number of donors donating in the last 12

months838,342 842,946 825,042 R Worse

Number of active O neg donors donating

over the last 12 months107,513 107,089 103,379 R -

Frequency of donation (overall) 1.836 1.849 1.864 G - Frequency of donation (O neg donors) 1.887 1.911 1.958 A -


Blood Components - Blood Donor Base

1.838

1.888

1.938

1.988

2.038

2.088

2.138

100,000

101,000

102,000

103,000

104,000

105,000

106,000

107,000

108,000

109,000

110,000

Ja

n-1

7

Fe

b-1

7

Ma

r-1

7

Apr-

17

Ma

y-1

7

Ju

n-1

7

Ju

l-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

O-neg Donors Donating O-neg Frequency

0

10,000

20,000

30,000

40,000

50,000

60,000

750,000

770,000

790,000

810,000

830,000

850,000

870,000

890,000

Ja

n-1

7

Fe

b-1

7

Ma

r-1

7

Ap

r-1

7

Ma

y-1

7

Jun-1

7

Jul-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

New Donors Registering New Donors Attending Donors Donating (All Groups)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

20

10

/11

FY

20

11

/12

FY

20

12

/13

FY

20

13

/14

FY

20

14

/15

FY

20

15

/16

FY

20

16

/17

FY

Ap

r-1

7

Ma

y-1

7

Ju

n-1

7

Ju

l-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

Ja

n-1

8

Fe

b-1

8

Ma

r-1

8

Donor Satisfaction - Actual Donor Satisfaction - Plan

0

1,000

2,000

3,000

4,000

5,000

6,000

7,000

8,000

0

200

400

600

800

1,000

1,200

Ap

r-15

Jun

-15

Au

g-1

5

Oct-

15

De

c-1

5

Feb-1

6

Ap

r-16

Jun

-16

Au

g-1

6

Oct-

16

De

c-1

6

Feb-1

7

Ap

r-17

Jun

-17

Au

g-1

7

Oct-

17

De

c-1

7

Ra

tio

/ m

illi

on

To

tal n

um

be

rs -

for

Co

mp

lain

an

ts

wit

h D

on

ati

on

s f

ac

tore

d b

y 1

/250 t

o

fit

ch

art

Collections/250 Complainants Complainants/million donations


25. Ro Donor Base and Black Donor Recruitment BC # 6 BC # 7 26. CD platelet Donor Base : Total and A Neg BC # 8 BC # 9


Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG

Trend

Number of Ro donors donating in the

last 12 months29,440 25,137 19,186 R -

Frequency of donation (overall) 1.836 1.860 1.866 G -


Blood Components - Blood Donor Base (continued)

The table below reports that the Component Donation donor base is substantially lower

than target. A flaw has been identified in the counting methodolgy, and this is the first

month where the actual counts have been restated (downwards). It is not possible to

restate historical counts.

Targets were based on the old counting methodology and will be restated. The correct

donor base and restated targets will be reported when available (with history from

September 2017 onwards).

Sep-2017 A- A+ AB- AB+ B- B+ O- O+ Total

777Target

Reviewed

report

Variance vs

target

2,365

-206

820 2,824 11,497

2,159 3,598 165 300 219 695 760 2,611 10,507

3,982 156 331 242

-60 -213 -990-384 9 -31 -23 -82

0

5,000

10,000

15,000

20,000

25,000

30,000

35,000

0

500

1,000

1,500

2,000

2,500

3,000

Ap

r-1

7

Ma

y-1

7

Ju

n-1

7

Ju

l-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

Jan-1

8

Feb

-18

Ma

r-1

8

Black Donors Registering New Black Donors Donating

Ro Donors donating (last 12 mths) Ro Donor base target

Ro

Do

no

rbase

Bla

ck

Do

no

rs


27. Processing Productivity : YTD and Current Month BC # 17 28. Testing Productivity : YTD and Current Month BC # 18

Annual

Target

YTD

Target

YTD

ActualRAG

YTD

RAG

Trend

Annual

Target

YTD

Target

YTD

ActualRAG

YTD

RAG

Trend

10,300 10,286 10,079 A - 29,700 29,710 28,887 A -

29. Blood Donation Productivity : YTD and Current Month BC # 19 30. Blood Donation Productivity - Distribution Mobile Teams

Annual

Target

YTD

Target

YTD

ActualRAG

YTD

RAG

Trend

1,411 1,410 1,395 G -

Blood Components - Productivity


YTD Performance

Testing productivity (units/FTE/year)

YTD Performance

Manufacturing productivity (units/FTE/year)

YTD Performance

Blood Donation Productivity (units/FTE/Year)

1,3

95

1,2

89

900

1,000

1,100

1,200

1,300

1,400

1,500

1,600

1,700

1,800

1,900

2008/0

9

2009/1

0

2010/1

1

2011/1

2

2012/1

3

2013/1

4

2014/1

5

2015/1

6

2016/1

7

2017/1

8 Y

TD

2017/1

8P

eri

od

EBA Top Quartile 1,752

10,0

79

9,9

96

4,000

5,000

6,000

7,000

8,000

9,000

10,000

11,000

2008/0

9

2009/1

0

2010/1

1

2011/1

2

20

12

/13

20

13

/14

20

14

/15

2015/1

6

2016/1

7

2017/1

8 Y

TD

2017/1

8P

eri

od

EBA Top Quartile 9,749

28,8

87

31,1

13

5,000

10,000

15,000

20,000

25,000

30,000

35,000

2008/0

9

2009/1

0

2010/1

1

2011/1

2

2012/1

3

2013/1

4

2014/1

5

2015/1

6

2016/1

7

2017/1

8 Y

TD

2017/1

8P

eri

od

EBA Top Quartile23,996

1,050

1,150

1,250

1,350

1,450

1,550

1,650

1,750

1,850

1,950

YTD Average includes static sites

23 above average

Slough (1,867)Reading (1,731)Teesside (1,644)

Tunbridge Wells (1,579)York (1,567)

26 below average

Plymouth (1,176)Liverpool (1,189)

Sheffield South (1,200)Sheffield North (1,202)Hertfordshire (1,221)

Top 5

Bottom 5


Page 17 of 35

DIVISION THEME STRATEGIC TARGET YTD RAG

RAG CHANGE PERFORMANCE

Sales Income (£69.3m) G - £56.1m (vs plan of £53.8m).

Number of Serious Incidents (SI’s) G - None reported this month

Zero ‘critical’ regulatory non-compliances G - None reported in the month.

Group Targets

Number of ‘major’ regulatory non-compliances R Worse 5 reported at the Birmingham ATU in the month.

Sales income achieved - £13.6m (chart 31) G - Marginally lower than plan at £9.6m (vs £9.8m).

80% percent of customers scoring =/> 9/10 for satisfaction with Tissues - - March 2017 (reported in April 2017) at 75%.

Tissue & Eye Services

98.0% of Product issued on time G - 99.4% vs plan of 98.0% (year to date).

Sales Income achieved - £13.9m (chart 32) A - £10.3m vs plan of £10.4m.

% of patients receiving A or B1 platelets A - 71% vs plan of 75% - Chart 2.

Time to type deceased organ donors G - Reporting monthly in arrears - at 85% vs target of 80%.

H&I

Turnaround time vs SLA (chart 36) G - Better than plan at 95.8% (vs 95% target).

£14.95m Sales income achieved (chart 32) G - £11.7m vs plan of £11.1m.

DTS

RCI Sample turnaround time vs SLA (chart 35) G - 96.1% vs plan of 95%.

Page 18 of 35


RAG CHANGE PERFOMANCE

£11.2m sales income achieved (chart 33) G - £8.6m vs plan of £8.4m. CMT

On time in full – target 100% G At target.

£9.8m sales income achieved (chart 33) G - £7.3m vs plan of £7.1m.

2,300 increase to Banked Cords TNC > 140 R - 1196 vs plan of 1724.

40% BAME Cord Blood units add to the bank G - 40% in the year to date (> 40).

Issue 75 Cord Blood units R Worse 41 units issued in the year to date (vs plan of 53).

Adult Donor Provisions (216) G - 173 vs plan of 157

SCDT

Donors recruited to fit panel – 10k A - 7,475 vs plan of 7,498

£7.6m sales income achieved (chart 34) G - £7.3m vs plan of £5.7m.

62% of hospitals scoring =/> 9/10 for satisfaction - - 70.5% vs 62% at February 2017.

DTS

Therapeutic Apheresis Services

95% of Patients rating patient experience =/>9/10 G - December 2017 at 97% (vs 95%)

• DTS is reporting an I&E surplus of £1.9m in the year to date. The forecast outturn for the year remains unchanged this month at a surplus of £0.8m. • Sickness absence in DTS was better this month at 2.6% and remains much better than the NHSBT target of 4%.

• All SBUs are reporting an I&E contribution at or better than plan in the year to date, with the exception of Tissues, which has seen a marked decline in the sales of

skin through the year (and is expected to continue through the year).

Page 19 of 35

DTS Income by SBU – YTD December 2017

2017/18 Budget

2017/18 Income

2017/18 Variance

2016/17 Actual Growth

Tissue & Eye Services 9.8 9.6 -0.2 9.1 6% TAS 5.7 7.2 1.5 5.5 30% H&I 10.4 10.3 -0.1 10.1 2% RCI 11.1 11.7 0.6 10.4 13% IBGRL 0.9 0.9 0.0 0.5 64% CMT 8.4 8.6 0.2 7.7 12% SCDT 7.4 7.6 0.3 7.5 2% Customer Services 0.1 0.1 0.0 0.1 -16%

Total (£m’s) 53.8 56.1 2.3

50.9 10%

• Tissue and Eye Services - income was significantly worse than plan in December. In the year to date it is now 2.1% worse than plan but remains 5.8% higher

than the previous year. Strong sales have been seen in corneas (£0.2m), ASE/AlloSE (£0.2m) and cardiovascular and are only partially offset by underperformance in skin (£0.5m), sclera (£0.1m), dCell dermis (£0.1m) and processed bone (£0.1m). There is a small favourable position on expenditure (£0.1m), which is partially offsetting income, but results in an adverse contribution position in the year to date (£0.2m). Eye bank stocks were stable at 313 at the end of December.

• RCI income continues to be 5.4% better than plan in the year to date and 13.2% higher than last year with antenatal referrals (£0.4m) and screening (£0.1m)

continuing to perform well. There is a small favourable position on expenditure (£0.1m) resulting in a surplus contribution year to date of £0.7m. Sample turnaround was again marginally lower than plan this month at 93.0%, although it continues to be better than plan in the year to date (96.1% vs 95.0%). The customer satisfaction results for the Q3 / December 2017 (56%) were lower than in the previous quarter (67%).

• H&I income is 1% behind plan in the year to date, although 2% higher than last year. Activity in stem cell investigations is 2% better than plan but this is more than

offset by general investigations and solid organ investigations which are 3% and 2% respectively below plan so far this year. Turnaround times have improved this month are now better than plan in the year to date (95.8% vs 95%). The provision of A and B1 matched platelets was 69% in December (70% November) and significantly worse than target (75%). In the year to date it remains below plan at 71%. In line with RCI, the H&I customer satisfaction results for Q3 / December 2017 (71%) were lower than in the previous quarter (77%).

• Stem Cell Donation & Transplantation income is showing a £0.4m favourable variance in the year to date. There have been 41 cord issues year to date (versus target of 53) with international 2 better than plan and the UK 14 below plan. BBMR donors are higher than plan in the year to date (173 versus target of 157) with the UK 5 behind plan and international 21 ahead of plan.

• The cords banked target was to have banked 20k by end of the 2018/19 financial year. At the current run rate, however, we will hit 20k by September 2019. At

this point the bank changes from a growth to a maintenance phase, and collection activity will be reduced (the TNC threshold will be increased so we are only banking A&B grade units at a rate of around 31per month - this will maintain the bank at 20k units and gradually improve the proportion of A&B cords). The slow

Page 20 of 35

down in the banking rate is due to a decision to leave posts vacant, and shifts uncovered, hence avoiding the need to recruit staff to reach target only to make them redundant next year. DH is in agreement with this approach as we are tracking towards the agreed bank size. The introduction of NICE guidelines on delayed cord clamping in March 2017 is now being implemented in hospitals and has impacted our clinical conversion rate. Taken together the number of cord units banked continues to run behind plan (31% lower in the year to date) and will report at red status through the rest of the year. BAME cord donations banked were equal with target in the month at 40% and in the year to date, remains level with plan.

• Cellular and Molecular Therapies - service income in the year to date is £0.2m better than budget and generating a small income and expenditure surplus

(£0.1m).

• Therapeutic Apheresis Services income in the year to date is 27% ahead of target and 30% higher than in the previous year, primarily due to strong performance on ECP (£1.2m), red cell exchange (£0.1m) and stem cell harvests (£0.2m). The income surplus (£1.5m), when combined with the increased expenditure to support these activity levels, is resulting in a favourable contribution surplus of £0.6m. The Patient Experience Survey achieved a Top Box score of 97%, with 5 out of 8 sites achieving 100%.

• There were 5 major regulatory findings reported as a result of an MHRA inspection on 9th January 2018 of the Advanced Therapies Unit in Birmingham. This is a

poor result (close to being a critical finding) and NHSBT will receive a Type 2 letter from the MHRA reflecting the seriousness of the findings and setting a tight timeframe for rectification. The findings were:

� Deficiencies within the Environmental Monitoring process with insufficient investigation of failures, inadequate evidence to support selection of monitoring points – HACCP analysis not performed, EM failures not reported as QIs, and no trend investigation

� Data Integrity � Control of change – including change control for Merlin not including changes to the process or sufficiently risk assess changes and licence not updated to

reflect changes in named personnel. � Personal locker in the GMP lobby area containing food and drink containers, rejected consumables, personal medication, and equipment with unclear

status. � Inadequate controls to minimise risks for sterile products eg aseptic operator technique, cellotape used in cloakroom, inadequate controls for sterile fill

validation testing

DTS – Status of Strategic Projects per TPB reportin g:

Project title Status This

RAG Last RAG

Approved Cost

(£m’s)

F/Cast Cost

(£m’s)


Planned to complete

F/Cast to complete

Stock Management Rollout(i) Closure N/A R 0.3 0.3 N/A Nov 17 Jan 18 TAS - Liverpool Delivery G G N/A N/A N/A Mar 20 Mar 20 Filton Extension Delivery G G 0.2 0.2 N/A Jan 21 Oct 21 Automated Software Testing Delivery G G N/A 0.2 N/A Nov 18 Mar 19

Notes: i) EPR due February 2018. Not reported to TPB this month.

31. Tissue and Eye Services Income (MAT) TS # 1 32. Diagnostic Service Income (MAT) H&I # 1 RCI # 1

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

14.884 11.138 11.741 G -13.882 10.398 10.319 A -

33. Stem Cells - SCDT/CMT Income (MAT) CMT # 1 SCDT # 1 34. Therapeutic Apheresis Services Income (MAT) TAS # 1

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

Annual

TargetYTD Target YTD Actual RAG

YTD RAG

Trend

11.212 8.410 8.563 G -

9.795 7.365 7.644 G -


Diagnostic and Therapeutic Services - Income

YTD Performance YTD Performance

-

YTD Performance

Income (£m's) - CMT

Income (£m's) - SCDT7.581 5.679 7.209 G

YTD Performance

Income (£m's) - TAS

A -Income (£m's) - H&I

Income (£m's) - TES 13.602 9.802 9.594Income (£m's) - RCI

7,000

8,000

9,000

10,000

11,000

12,000

13,000

14,000

15,000

Ap

r-1

4

Ju

n-1

4

Au

g-1

4

Oct-

14

Dec-1

4

Fe

b-1

5

Ap

r-1

5

Ju

n-1

5

Au

g-1

5

Oct-

15

Dec-1

5

Fe

b-1

6

Ap

r-1

6

Ju

n-1

6

Au

g-1

6

Oct-

16

Dec-1

6

Fe

b-1

7

Ap

r-1

7

Ju

n-1

7

Au

g-1

7

Oct-

17

Dec-1

7

Fe

b-1

8

£000

s

TES Actual TES Budget

11,500

12,000

12,500

13,000

13,500

14,000

14,500

15,000

15,500

16,000

Ap

r-1

4

Jun

-14

Au

g-1

4

Oct-

14

Dec-1

4

Fe

b-1

5

Ap

r-1

5

Jun

-15

Au

g-1

5

Oct-

15

Dec-1

5

Fe

b-1

6

Ap

r-16

Ju

n-1

6

Au

g-1

6

Oct-

16

Dec-1

6

Fe

b-1

7

Ap

r-17

Ju

n-1

7

Au

g-1

7

Oct-

17

Dec-1

7

Fe

b-1

8

£000s

H&I Actual RCI Actual H&I Budget RCI Budget

5,000

5,500

6,000

6,500

7,000

7,500

8,000

8,500

9,000

9,500

10,000

Ap

r-14

Jun

-14

Au

g-1

4

Oct-

14

De

c-1

4

Feb-1

5

Ap

r-1

5

Ju

n-1

5

Au

g-1

5

Oct-

15

De

c-1

5

Feb-1

6

Ap

r-16

Jun

-16

Au

g-1

6

Oct-

16

De

c-1

6

Feb-1

7

Ap

r-1

7

Ju

n-1

7

Au

g-1

7

Oct-

17

De

c-1

7

Feb-1

8

£000s

TAS Actual TAS Target

6,000

7,000

8,000

9,000

10,000

11,000

12,000

13,000

Ap

r-14

Jun

-14

Au

g-1

4

Oct-

14

Dec-1

4

Fe

b-1

5

Ap

r-15

Jun

-15

Au

g-1

5

Oct-

15

Dec-1

5

Fe

b-1

6

Ap

r-16

Jun

-16

Au

g-1

6

Oct-

16

De

c-1

6

Fe

b-1

7

Ap

r-17

Jun

-17

Au

g-1

7

Oct-

17

De

c-1

7

Fe

b-1

8

£000

s

CMT Actual SCDT Actual CMT Budget SCDT Budget


35. Turnaround Time vs SLA (RCI) RCI # 5 36. Turnaround Time vs SLA (H&I) H&I # 7

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

95.0% 95.0% 96.1% G - 95.0% 95.0% 95.8% G -

37. Hospital Satisfaction H&I # 3 RCI # 3 38. Major QI's raised per month - DTS

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

61% 61% 56% A Worse

61% 61% 71% G -Percent of hospitals scoring =/> 9/10

for satisfaction with H&I - RCI


Diagnostic and Therapeutic Services - Customer service and safety

Percentage of hospitals scoring =/>

9/10 for satisfaction with RCI - RCI

Turnaround Time vs SLA - H&I

YTD Performance

YTD Performance

Turnaround Time vs SLA - RCI

YTD Performance

60% 61% 61% 61%

53%

74%

67%

56%60% 61% 61% 61%

74%

92%

77%

71%

40%45%50%55%60%65%70%75%80%85%90%95%

Mar-

17

Jun

-17

Se

p-1

7

Dec-1

7

RCI Target RCI Survey H&I Target H&I Survey

86.0%

88.0%

90.0%

92.0%

94.0%

96.0%

98.0%

100.0%

Ap

r-15

May-1

5

Jun

-15

Jul-1

5

Au

g-1

5

Se

p-1

5

Oct-

15

Nov-1

5

Dec-1

5

Jan

-16

Feb-1

6

Ma

r-16

Ap

r-16

Ma

y-1

6

Jun

-16

Jul-1

6

Au

g-1

6

Se

p-1

6

Oct-

16

Nov-1

6

Dec-1

6

Jan

-17

Fe

b-1

7

Ma

r-17

Ap

r-17

Ma

y-1

7

Jun

-17

Jul-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

Nov-1

7

Dec-1

7

RCI Target RCI sample turnaround time vs SLA

84.0%

86.0%

88.0%

90.0%

92.0%

94.0%

96.0%

98.0%

100.0%

Ap

r-15

May-1

5

Jun

-15

Jul-1

5

Au

g-1

5

Se

p-1

5

Oct-

15

Nov-1

5

Dec-1

5

Jan

-16

Fe

b-1

6

Ma

r-16

Ap

r-16

Ma

y-1

6

Jun

-16

Jul-1

6

Au

g-1

6

Se

p-1

6

Oct-

16

Nov-1

6

Dec-1

6

Jan

-17

Fe

b-1

7

Mar-

17

Ap

r-17

Ma

y-1

7

Jun

-17

Jul-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

Nov-1

7

Dec-1

7

H&I target H&I sample turnaround time vs SLA

0

2

4

6

8

10

12

14

16

18

Ja

n-1

7

Fe

b-1

7

Ma

r-17

Ap

r-1

7

Ma

y-1

7

Ju

n-1

7

Jul-

17

Au

g-1

7

Se

p-1

7

Oct-

17

Nov-1

7

De

c-1

7

BBMR H&INHS Cord Bank RCICMT Tissue ServicesTAS IBGRL - Molecular DiagnosticsCustomer Services


39. Adult donor provisions : UK and International - MATs SCDT # 8 40. Issue of cord blood units : UK and International - MATs SCDT # 7

SCDT # 8 SCDT # 8

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

216 157 173 G - 75 53 41 R -

41. Suitable Cornea Donations - MAT, and Cornea stocks 42. NHSBT CBB stock (active units - cell dose post process TNC) SCDT # 5

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

2,300 1,724 1,196 R -

Adult donor provisions (total)


Stem Cell Donation and Transplantation, and Tissue and Eye Services : Corneas - Strategic Targets

YTD Performance

Banked Donations TNC > 140

YTD Performance

YTD Performance

Number of Cord Units Issued (total)

30

50

70

90

110

130

150

170

Ap

r-14

Ju

n-1

4

Au

g-1

4

Oct-

14

De

c-1

4

Fe

b-1

5

Ap

r-15

Ju

n-1

5

Au

g-1

5

Oct-

15

De

c-1

5

Fe

b-1

6

Ap

r-16

Ju

n-1

6

Au

g-1

6

Oct-

16

De

c-1

6

Fe

b-1

7

Ap

r-17

Ju

n-1

7

Au

g-1

7

Oct-

17

De

c-1

7

Fe

b-1

8

UK MAT International MAT UK Target International Target

200

220

240

260

280

300

320

340

360

3,600

3,800

4,000

4,200

4,400

4,600

Jan

-17

Feb-1

7

Mar-

17

Ap

r-17

May-1

7

Jun

-17

Jul-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

Nov-1

7

Dec-1

7

Co

rnea S

tock

Su

itab

le C

orn

ea D

on

ati

on

s M

AT

MAT Suitable Cornea Donations Cornea Stock

7,798

11,178

4,247

1,445

0

2,000

4,000

6,000

8,000

10,000

12,000

Less than 90 TNC(Research grade)

Between 90 to 139 TNC(Operational C Grade)

Between 139 to 190 TNC(Operational B Grade)

Greater than 190 TNC(Operational A Grade)

0

10

20

30

40

50

60

Apr-

14

Ju

n-1

4

Aug

-14

Oct-

14

Dec-1

4

Feb

-15

Apr-

15

Ju

n-1

5

Aug

-15

Oct-

15

Dec-1

5

Feb

-16

Apr-

16

Ju

n-1

6

Aug

-16

Oct-

16

Dec-1

6

Feb

-17

Apr-

17

Ju

n-1

7

Aug

-17

Oct-

17

Dec-1

7

Feb

-18

UK MAT International MAT UK Target International Target


Page 24 of 35

. • There have been 1,129 deceased donors in the year to date, 14 lower than target. This equates to a 7.5% increase compared with the same period last year

with an 11.5% increase in DBD and a 2% increase in DCD. • The DBD and DCD SNOD presence rates in the year to date remain at 95% and 85% respectively. This equates to an overall year to date SNOD presence

rate of 90% versus 86% last year. There were 26% (87) fewer occasions where families were approached for a formal organ donation discussion without a SNOD present in the year to date, compared with the same nine months last year. This equates to a 26% decrease. Regions have reported several reasons why no SNOD was present at the formal approach for donation:


RAG CHANGE PERFORMANCE

Increase % Consent/Authorisation rate (Overall) A - 65.0% year to date vs plan of 70% - chart 55.

Increase % Consent/Authorisation rate (Overall) – DBD G - 73.2% in December year to date vs plan of 73%.

Increase % Consent/Authorisation rate (Overall) - DCD R - 58.5% year to date vs plan of 67%.

Deceased donors - 2017/18 target – 1,524 G - Year to date at 1,129 vs target of 1,143 – chart 43.

Deceased Organ Donors per million population G - September - 22.8m vs plan 23.0m. Next report March 2018

Number of Living donors 2016/17 (1,260) – reported one month in arrears R - Year to date (Nov) at 691 vs plan of 928 – chart 46.

Living Donors per million population – 19.0 per/m - - September at 15.9m vs plan 18.7m (update in January).

Internal NHSBT target based on 1.1m new registrations in 2017/18. G - New registrations are 0.913m year to date (vs 0.825m)

Organ Transplants – Deceased (4,116) A - 2,887 year to date vs plan of 3,087 – chart 44.

Deceased Organ Transplants per million population. A - 58.7m vs plan 62.1m. Next report March 2018

Proportion of population who have had a conversation about their donation decision (target 47%) - - New measure - next report February 2018

ODT

TOT 2020 Key Outcome Measures

NHSBT Cost per Transplant (chart 45). - £16.3k (2017/18 target) G - December at £16.6k. Next update March 2018.

Page 25 of 35

- 2 cases where SNOD en route to hospital (1 re-approached); - 4 cases where there was no referral to SNOD team; - 2 cases where the SNOD was unable to attend due to activity (clinical team coached by SR on approach); - 2 cases where SNOD was over 3 hours away and family wanted withdrawal; - 3 cases where Clinical team were discussing withdrawal of treatment but discussed donation at the same time; - 6 cases where the SNOD was present on the ICU however were refused to be allowed into the conversation.

• The overall consent rate in the year to date remains at 65% versus the 62% achieved in the same nine months last year. • Formal organ donation discussions have taken place with patients from black and Asian communities on 42 more occasions than last year to date with

consent being achieved on 40 more occasions. The overall consent rate for patients from black and Asian communities is 43% (110 out of 257) in the year to date, 10% higher than in the same nine months last year. Q3, however, was considerably lower than the consent rate achieved in Q2.

• There were 24 ODR overrides in Q1, 21 in Q2 and 15 in Q3, equating to 60 in the year to date.. In total there have been 7 fewer ODR overrides in the year

to date compared to last year. 12 of the 60 ODR overrides in the year to date have happened without a SNOD present. If a SNOD had been present, consent may have been ascertained on 10 more occasions in the year to date, assuming a 94% consent rate achieved by the SNODs.

• For patients known to have opted-in on the ODR, the quarterly consent rates in 2017/18 were as follows:

- SNOD present: Q1=93%, Q2=92%, Q3=95%, and in the year to date is 94% (1% higher than same nine months last year). - SNOD not present: Q1=33% (3/9), Q2=73% (8/11), Q3=79% (11/14), and in the year to date is 65% (22/34).

• For patients who had not opted-in on the ODR, or this was not known at the time, the quarterly consent rates in 2017/18 have been:

- SNOD present: Q1=57%, Q2=56%, Q3=60%, YTD=58% (<1% higher than same nine months last year) - SNOD not present: Q1=8% (6/75), Q2=13% (9/71), Q3=11% (8/72), YTD=11% (23/218) If a SNOD had been present on the 218 occasions, consent may have been ascertained on 103 more occasions in the year to date (in addition to the 23 achieved), assuming a 58% consent rate achieved by the SNODs.

. • The increase in deceased donor transplants is not as great as the increase in deceased donors being 4.4% higher than last year to date and 200 lower than

target. • December was a poor month for registrations with only 69,833 new opt-in registrations but are ahead of the annual target for 1.1 million new opt-in

registrations, with 913k in the year to date. The DVLA data transfer feed was significantly lower than usual in December and is the main reason for the drop in new registrations. 43% of new registrations came through digital activity (compared to 34% the previous month). This increased proportion of digital registrations reflects both the reduction in data feed registrations through the DVLA and England and Wales GP service as well as the launch of the Government’s consultation which prompted a spike in web visits and online sign ups on the 12th December. It is important to note that the Scottish GP Service is inactive. There is an error in the source data that is currently being worked through by the third party provider. The NHS Tracing Service & De-Duplication Process has also been inactive since June 2015. This may result in significant numbers of duplicate registrations on the live ODR i.e. over-reporting the number of registrants.

• Absence decreased marginally following a reduction in long term absence. In total short term absence is at 2.29% and long term absence at 1.43%. There are five teams with absence above 4%: Eastern, Northern Ireland, Northern, South Central and South Wales.

Page 26 of 35

.

. ODT – Status of Strategic Projects per TPB reportin g:


Last RAG

Approved Cost

(£m’s)

F/Cast Cost

(£m’s)


Planned to complete

F/Cast to complete

ODT Hub Define G G 3.2(i) (0.6) N/A(ii) N/A Dec 19 Dec 19

Notes: i) This is non-recurring figure for 2017/18, recurring figure in brackets. ii) Now an under spend of £403k.

43. MAT number of Deceased Organ Donors ODT # 4 44. MAT number of Deceased Donor Organ Transplants ODT # 9


Target

YTD

Target

YTD

ActualYTD RAG

YTD RAG


Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

Number of Deceased Organ Donors 1,524 1,143 1,129 G - Number of Deceased Donor Transplants 4,116 3,087 2,887 A -

45. ODT Cost per Donor/Transplant ODT # 11 46. MAT number of Live Organ Donors (reported one month in arrears) ODT # 6

Annual

Target

Forecast

for the

year

YTD RAGYTD RAG


Annual

Target

YTD

Target

YTD

ActualYTD RAG

YTD RAG

Trend

16.2 16.4 G -Number of Living Organ Donors (reported

one month in arrears)1,392 928 691 R -


Organ Donation and Transplant - Outcomes

YTD Performance

NHSBT Cost per Transplant (£k's)

0

500

1000

1500

2000

2500

3000

3500

4000

4500

0

10

20

30

40

50

60

70

80

10/11 11/12 12/13 13/14 14/15 15/16 16/17 Budget17/18

Forecast17/18

Do

no

rs/T

ran

sp

lan

ts (

No

.)

£

ODT Total Spend (£M) Cost per donor (£K) Cost per transplant (£K)

Transplants (No.) Donors (No.)

1418

1432

1445

1447

1465

1473

1482

1484

1492

1524

17

64

1000

1100

1200

1300

1400

1500

1600

1700

1800

Apr-

17

Ma

y-1

7

Jun-1

7

Ju

l-17

Au

g-1

7

Se

p-1

7

Oct-

17

Nov-1

7

Dec-1

7

Jan-1

8

Fe

b-1

8

Ma

r-1

8

Ma

r-1

9

Ma

r-2

0

Ma

r-2

1

Ma

r-2

2

MAT Actual MAT Plan

3708

3760

3769

3786

3828

3866

3874

3858

3836 4

116

5028

2800

3100

3400

3700

4000

4300

4600

4900

5200

Apr-

17

Ma

y-1

7

Jun-1

7

Ju

l-17

Aug

-17

Sep

-17

Oct-

17

No

v-1

7

De

c-1

7

Ja

n-1

8

Feb-1

8

Ma

r-18

Ma

r-19

Mar-

20

Ma

r-21

Mar-

22

MAT Actual MAT Plan

1018

1027

1031

1030

1047

1044

1033

1007

1392

900

950

1000

1050

1100

1150

1200

1250

1300

1350

1400

1450

Ap

r-17

May-1

7

Ju

n-1

7

Ju

l-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

Ja

n-1

8

Fe

b-1

8

Mar-

18

MAT Actual MAT Plan


47. MAT number of Deceased Organ Donors (DBD) 48. Deceased Organ Donors - Monthly (DBD)

49. Deceased Organ Donors - Weekly (DBD) 50. Deceased Organ Donors - By Nation (DBD)


Organ Donation and Transplant - DBD Activity

0

5

10

15

20

25

30

Ap

ril

May

Jun

e

July

Au

gust

Se

pte

mber

Octo

ber

Decem

ber

Jan

uary

Febru

ary

Marc

h

2017/18 Plan (DBD) 2017/18 Actual (DBD) 2016/17 Actual (DBD)

0

100

200

300

400

500

600

700

En

gla

nd

Wale

s

Scotland

No

rth

ern

Irela

nd

Organ donors YTD December 2016/17 (DBD) Organ donors YTD December 2017/18 (DBD)8

99

87

3

500

550

600

650

700

750

800

850

900

950

1000

Ap

r-1

6

May-1

6

Jun

-16

Jul-

16

Au

g-1

6

Se

p-1

6

Oct-

16

Nov-1

6

Dec-1

6

Jan

-17

Fe

b-1

7

Ma

r-1

7

Ap

r-1

7

May-1

7

Jun

-17

Jul-

17

Au

g-1

7

Se

p-1

7

Oct-

17

Nov-1

7

Dec-1

7

Jan

-18

Fe

b-1

8

Ma

r-1

8

DBD MAT Actual DBD MAT Target

0

10

20

30

40

50

60

70

80

90

100


2016/17 DBD Actual 2017/18 DBD Actual 2017/18 DBD Target


51. MAT number of Deceased Organ Donors (DCD) 52. Deceased Organ Donors - Monthly (DCD)

53. Deceased Organ Donors - Weekly (DCD) 54. Deceased Organ Donors - By Nation (DCD)


Organ Donation and Transplant - DCD Activity

0

2

4

6

8

10

12

14

16

18

20

Ap

ril

May

Jun

e

July

Au

gust

Se

pte

mber

Octo

ber

Decem

ber

Jan

uary

Febru

ary

Marc

h

2017/18 Plan (DCD) 2017/18 Actual (DCD) 2016/17 Actual (DCD)

0

50

100

150

200

250

300

350

400

450

En

gla

nd

Wale

s

Sco

tla

nd

No

rth

ern

Ire

land

Organ donors YTD December 2016/17 (DCD) Organ donors YTD December 2017/18 (DCD)5

93

62

3

450

500

550

600

650

Apr-

16

May-1

6

Ju

n-1

6

Jul-16

Aug-1

6

Se

p-1

6

Oct-

16

Nov-1

6

De

c-1

6

Ja

n-1

7

Feb-1

7

Ma

r-1

7

Ap

r-1

7

May-1

7

Ju

n-1

7

Ju

l-1

7

Aug-1

7

Sep-1

7

Oct-

17

Nov-1

7

Dec-1

7

Ja

n-1

8

Fe

b-1

8

Mar-

18

DCD MAT Actual DCD Target

0

10

20

30

40

50

60

70


2016/17 DCD Actual 2017/18 DCD Actual 2017/18 DCD Target


55. Consent / Authorisation rate (DBD & DCD) ODT # 1 56. Consent/Authorisation rate (DBD) per month ODT # 2


Target

YTD

Target

YTD

ActualYTD RAG

YTD RAG


Annual

Target

YTD

Target

YTD

ActualYTD RAG

YTD RAG

Trend

Consent/Authorisation rate (%) 70.0% 70.0% 65.0% A - DBD Consent/Authorisation rate (%) 73.0% 73.0% 73.2% G -

57. Consent/Authorisation rate (DCD) per month ODT # 3 58. Number of people registered on the ODR (opt-ins) ODT # 8


Target

YTD

Target

YTD

ActualYTD RAG

YTD RAG


Annual

Target

YTD

Target

YTD

ActualYTD RAG

YTD RAG

Trend

DCD Consent/Authorisation rate (%) 67.0% 67.0% 58.5% R - Opt-in registrants on the ODR (millions) 1.100 0.825 0.913 G -


Organ Donation and Transplant - Consent / ODR

000's

0.00

5.00

10.00

15.00

20.00

25.00

30.00

Ap

r-1

6

Ma

y-1

6

Ju

n-1

6

Jul-

16

Au

g-1

6

Sep-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan-1

7

Fe

b-1

7

Ma

r-1

7

Ap

r-1

7

Ma

y-1

7

Jun-1

7

Ju

l-1

7

Aug-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

Ja

n-1

8

Feb

-18

Ma

r-1

8

Registrants Target

50%

54%

58%

62%

66%

70%

74%

0

50

100

150

200

250

300

350

Jan-1

7

Feb

-17

Ma

r-1

7

Apr-

17

Ma

y-1

7

Ju

n-1

7

Jul-

17

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

Approach Consent Percent Target %

50%

54%

58%

62%

66%

70%

74%

78%

82%

0

20

40

60

80

100

120

140

160

Ja

n-1

7

Fe

b-1

7

Ma

r-1

7

Apr-

17

Ma

y-1

7

Jun-1

7

Ju

l-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

Eligible DBD family approached DBD family consents Target Consent % Mthly%

46.0%

50.0%

54.0%

58.0%

62.0%

66.0%

70.0%

74.0%

0

20

40

60

80

100

120

140

160

180

200

Jan-1

7

Feb

-17

Ma

r-1

7

Ap

r-1

7

Ma

y-1

7

Ju

n-1

7

Jul-1

7

Aug-1

7

Sep-1

7

Oct-

17

No

v-1

7

De

c-1

7

Eligible DCD family approached DCD family consents Target Consent % Mthly%


59. Transplantable Organs per Donor 60. ODT Hub Operations - Incidents per Organ Offer

61. ODT Absence rate (%) 62. Annual Turnover rate (%)


Organ Donation and Transplant - Absence/Turnover

Organ Donation and Transplant - Transplantable Organs and Duty Office Incidents

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

Jan-1

7

Feb

-17

Ma

r-1

7

Apr-

17

Ma

y-1

7

Jun-1

7

Jul-1

7

Aug-1

7

Sep-1

7

Oct-

17

No

v-1

7

De

c-1

7

DBD (Actual) DCD (Actual)

%

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

Jan

-17

Feb-1

7

Mar-

17

Ap

r-17

May-1

7

Jun

-17

Jul-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

Nov-1

7

Dec-1

7

ODT Overall % Absence Organ Donation % Absence Transplant Support Services % Absence

0

5

10

15

20

25

30

Jan

-17

Feb-1

7

Mar-

17

Ap

r-17

May-1

7

Jun

-17

Jul-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

Nov-1

7

Dec-1

7

ODT % turnover Organ Donation % turnover Transplant Support Services % turnover

0

500

1,000

1,500

2,000

2,500

3,000

3,500

0.00%

0.20%

0.40%

0.60%

0.80%

1.00%

Jan-1

7

Feb

-17

Ma

r-1

7

Apr-

17

Ma

y-1

7

Jun-1

7

Jul-1

7

Aug-1

7

Sep-1

7

Oct-

17

No

v-1

7

De

c-1

7

Incid

en

t R

ate

Incident Rate Organ Offers made


Page 32 of 35

SECTOR NOTES/UPDATE REPORT

NHSBT Corporate

Sickness absence was a slightly higher this month at 3.6% but equal to last year. As previously noted a sustained and significant improvement within logistics is supporting the overall performance seen in NHBST. Health and Safety – the Lost Time Incidence Rate (12 months to November 2017) is at 1.7 (a welcome decrease from last month of 0.2). Exercise “Fulcrum”, designed for the National Emergency Team (NET), will be held in January or February. The aim of the exercise is to run a NET in as realistic a manner. The date is therefore confidential and staff will be asked to take part in the exercise via teleconference. In response to the NHS marking its 70th birthday in 2018, building to a national celebration on 5th July, NHSBT will be putting NHS70 branding on our websites and other materials. We hope to involve the B Positive choir in national events, celebrate with our donors and align our staff awards with the birthday year.

Corporate - Status of Strategic Projects per TPB re porting:


Last RAG

Approved Cost

(£m’s)

F/Cast Cost

(£m’s)


Planned to complete

F/Cast to complete

Networks & Telephony Contract Delivery R A 1.6 1.4 0.1 Apr 17 May 18 Barnsley Project (Leeds Sheffield) Delivery G G 16.5 16.5 1.1 Jan 21 Jan 21 Desktop Modernisation – Infrastructure Improvement Delivery G G 3.5 2.2 N/A Apr 17 Feb 18

QPulse Performance Remediation & Upgrade Delivery G G 0.1 0.1 N/A TBC Feb 18

Exchange On-Line Migration Delivery G G 0.6 N/A N/A TBC Jul 18 Pulse GUI/Middleware Server Upgrade Delivery G G 0.6 N/A N/A TBC Apr 18

Portfolio and Resource Management Start-Up G G N/A N/A N/A TBC May 18 Robotic Process Automation Start-Up G G N/A N/A N/A TBC Feb 18 Tooting 2nd Floor Delivery G G 0.4 0.4 0.3 Jan 18 Jan 18 Pager Replacement(i) Start-Up N/A N/A 0.1 0.1 N/A Aug 18 Feb 18

Notes: i) Not reported this month as this project will be covered under the Hub Programme Pack and will go to Hub PgM Board & ODT CPB..

63. IT system performance 64. Health and Safety - Accident Reporting

Period

Target

Period

Actual

Period

RAG

RAG

Trend

Level 1&2

MAT Target

Level 1&2 MAT

Total

Level 1-3

Mthly Target

Level 1-3

Period Actual

<=17 12 <=24 9

<=6 4 <=4.5 2

<=1 1 <=2 1

0 0 <=1 0

0 0 <=1 0

<=24 17 <=32.5 12

65. Quality System >30 days Overdue Items 66. Sickness Absence

Directorate (as at 08 Jan) DocumentsQuality

Incidents

Adverse

Events

Change

Control

Audit

FindingsTOTAL

DTS 12 20 2 18 52

M&L 3 22 4 4 4 37

ICT 4 3 7

QA 5 5

BD 3 2 5

All Other 2 4 2 1 9

Total 15 51 10 11 28 115

Pulse

G

Better

NHSBT

M&L

Organ Donation

Group Services99.95% 99.77% A Worse

DTS/SpS

Worse

EOS

NtXD

R

G Better

99.95% 100.00% Better

-

100.00% G

99.95% 100.00% G

99.95%


NHSBT Corporate - ICT / Workforce

System availability

100.00% G BetterDonor Portal 99.95%

H&S Incident Levels (x 1 mth

in arrears)

Blood Donation

TMS

OBOS 99.95% 99.02%

Hematos

99.95% 100.00%

12

0

10

20

30

Dec-1

6

Jan

-17

Feb-1

7

Mar-

17

Ap

r-17

May-1

7

Jun

-17

Jul-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

Nov-1

7

Blood Supply - MTI / Donation DTS Organ Donation Group Services NHSBT Total

2017/18 Monthly Target (33)

2.50%

3.50%

4.50%

5.50%

6.50%

7.50%

8.50%

Jan

-17

Feb-1

7

Mar-

17

Ap

r-17

May-1

7

Jun

-17

Jul-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

Nov-1

7

Dec-1

7

NHSBT Blood Donation Logistics

0

50

100

150

200

250

300

350

15 May 17 19 Jun 17 17 Jul 17 14 Aug 17 11 Sep 17 09 Oct 17 13 Nov 17 11 Dec 17 08 Jan 18

>30 days Quality System Overdue Items

DTS Blood ODT All Other


Page 34 of 35

RISK MANAGEMENT Risk register summary ( net risk) and summary by themes

Corporate Risk Register Summary Red Amber Green

130 12 112 6

The dependency and reliance on the SME that currently provides support for our critical operational systems (PULSE/Hematos) and, in particular, their ability to retain the necessary capability and service levels as we transition away to new systems as part of the CSM project. The ability to supply in case of the loss of a key facility (e.g. Filton, Speke) or the loss of critical IT systems (Pulse, Hematos, networks etc). The risk of critical system loss is increasing on the back of the significant changes that are planned (e.g. new desktop, CSM etc.) and the significant complexity and inter-dependency between them. Inability to supply as a result of planning / supply challenges through: • (at the macro level) limited visibility with regard to longer term blood demand trends and especially when current demand decline

will be offset by the anticipated impact of demographic trends • significant differential short term demand trends at group / component level (eg O neg red cells, A neg platelets) The scale of the transformation programme across NHSBT will create a significant challenge on the capacity and capability of NHSBT to safely execute the change (both ICT and business resources) and a potential distraction to delivering business as usual. The ability to avoid blood price rises is highly dependant on our ability to manage the combined impact of : • the increased cost of CSM (and uncertainty regarding the phasing of the spend and timescale) • the organisational focus required to safely implement CSM and a slow down in the delivery of underlying BAU efficiency

improvements • ongoing reduction in red cell demand and the loss of related income and contribution • being able to generate significant productivity improvements in Blood Donation especially (given the inherent productivity gap

and high contribution to overall costs) and the significant impact on service configuration required. • the marketing costs needed to re-build / re-balance the blood donor base Ongoing reduction in demand will require significant changes to the configuration of blood collection services in order to not just maintain productivity but deliver the increased Blood 2020 targets. This would involve fewer / larger mobile sessions, greater use of fixed donor venues and much less collection activity in certain parts of the country. This could result in adverse donor reaction (and potentially attendance) if not managed and communicated well and an impact on supply if, for example, sufficient numbers of O neg donors cannot be retained. The high prevalence of manual, paper based and verbal processes throughout NHSBT’s operations, especially within reference testing and in the duty office within organ donation and transplant. Although these are mitigated by appropriate manual control checks, and new systems are removing transcription in some areas, there is a residual risk that these are ineffective and cause transcription errors that could lead to the death or harm of NHS patients.

Page 35 of 35

RISK MANAGEMENT Risk register summary ( net risk) and summary by themes (cont.)

Risk to delivery of TOT 2020 strategic targets driven by : • adverse trends in the organ donor pool • inability to change consent levels • lack of funding required for supporting business cases in respect of consent strategy and new technologies • lack of transplant capacity. Changing clinical/commissioning intentions in Stem Cells (ie Cord Blood / BBMR) as a recommended treatment, may impact on the outcomes and therefore the future viability of these services.

There are no new high/extreme risk’s this month: There is a risk that significant numbers of donors may need to be deferred as a result of the impact of the Interval/Compare trials which has not yet been formally escalated through the risk register. If this risk were to materialise it would represent a threat to supply and mitigation would require a significant increase in active donor numbers (with a resulting increase in marketing costs) and introduction of more accurate iron testing (also at increased cost).